EUVIMEDEUVIMED entdecken
Open Access

The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses

David R Martinez iD, Fernando R Moreira, Nicholas J Catanzaro iD, Meghan V Diefenbacher, Mark R Zweigart iD, Kendra L Gully iD, Gabriela De la Cruz iD, Ariane J Brown, Lily E Adams iD, Boyd Yount, Thomas J Baric iD, Michael L Mallory iD und 20 weitere

Science Translational Medicine · 22.05.2024 · 16 (748)

DOI: 10.1126/scitranslmed.adj4504 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 22.05.2024. Verfasst von David R Martinez und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunobiology, Yale School of Medicine, New Haven, CT 06510, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Prodrugs, Antiviral Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the wide availability of several safe and effective vaccines that prevent severe COVID-19, the persistent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that can evade vaccine-elicited immunity remains a global health concern. In addition, the emergence of SARS-CoV-2 VOCs that can evade therapeutic monoclonal antibodies underscores the need for additional, variant-resistant treatment strategies. Here, we characterize the antiviral activity of GS-5245, obeldesivir (ODV), an oral prodrug of the parent nucleoside GS-441524, which targets the highly conserved viral RNA-dependent RNA polymerase (RdRp). We show that GS-5245 is broadly potent in vitro against alphacoronavirus HCoV-NL63, SARS-CoV, SARS-CoV–related bat-CoV RsSHC014, Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 WA/1, and the highly transmissible SARS-CoV-2 BA.1 Omicron variant. Moreover, in mouse models of SARS-CoV, SARS-CoV-2 (WA/1 and Omicron B1.1.529), MERS-CoV, and bat-CoV RsSHC014 pathogenesis, we observed a dose-dependent reduction in viral replication, body weight loss, acute lung injury, and pulmonary function with GS-5245 therapy. Last, we demonstrate that a combination of GS-5245 and main protease (M pro ) inhibitor nirmatrelvir improved outcomes in vivo against SARS-CoV-2 compared with the single agents. Together, our data support the clinical evaluation of GS-5245 against coronaviruses that cause or have the potential to cause human disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2ProdrugsAntiviral AgentsAnimalsHumansMiceAdministration, OralChlorocebus aethiopsVero CellsCOVID-19 Drug TreatmentCOVID-19Virus ReplicationNucleosidesFemaleDisease Models, Animal

Substanzen

ProdrugsAntiviral AgentsNucleosides

Autor:innen und Institutionen

  • Department of Immunobiology, Yale School of Medicine, New Haven, CT 06510, USA.
  • Yale Center for Infection and Immunity, Yale School of Medicine, New Haven, CT 06510, USA.
  • Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.
  • Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.
  • Gilead Sciences, Inc., Foster City, CA 94404, USA.

ORCID-Profile: David R Martinez, Nicholas J Catanzaro, Mark R Zweigart, Kendra L Gully, Gabriela De la Cruz, Lily E Adams, Thomas J Baric, Michael L Mallory, Stephanie Dong, Cameron Nguyen, Stephanie A Montgomery, Jason K Perry, Darius Babusis, Kimberly T Barrett, Anh-Quan Nguyen, Roy Bannister, Joy Y Feng, Ralph S Baric, John P Bilello, Alexandra Schäfer, Timothy P Sheahan

Förderung

  • NIAID NIH HHS

Zitieren

APA

Martinez, D. R., Moreira, F. R., Catanzaro, N. J., Diefenbacher, M. V., Zweigart, M. R., Gully, K. L., De la Cruz, G., Brown, A. J., Adams, L. E., Yount, B., Baric, T. J., Mallory, M. L., Conrad, H., May, S. R., Dong, S., Scobey, D. T., Nguyen, C., Montgomery, S. A., Perry, J. K., …, & Sheahan, T. P. (2024). The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses. Science Translational Medicine, 16(748). https://doi.org/10.1126/scitranslmed.adj4504

Vancouver

Martinez DR, Moreira FR, Catanzaro NJ, Diefenbacher MV, Zweigart MR, Gully KL, et al. The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses. Science Translational Medicine. 2024;16(748). doi:10.1126/scitranslmed.adj4504

BibTeX
@article{Martinez2024,
  author = {Martinez, David R and Moreira, Fernando R and Catanzaro, Nicholas J and Diefenbacher, Meghan V and Zweigart, Mark R and Gully, Kendra L and De la Cruz, Gabriela and Brown, Ariane J and Adams, Lily E and Yount, Boyd and Baric, Thomas J and Mallory, Michael L and Conrad, Helen and May, Samantha R and Dong, Stephanie and Scobey, D Trevor and Nguyen, Cameron and Montgomery, Stephanie A and Perry, Jason K and Babusis, Darius and Barrett, Kimberly T and Nguyen, Anh-Hoa and Nguyen, Anh-Quan and Kalla, Rao and Bannister, Roy and Feng, Joy Y and Cihlar, Tomas and Baric, Ralph S and Mackman, Richard L and Bilello, John P and Schäfer, Alexandra and Sheahan, Timothy P},
  title = {The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses},
  journal = {Science Translational Medicine},
  year = {2024},
  volume = {16},
  number = {748},
  doi = {10.1126/scitranslmed.adj4504}
}
Kostenlos starten →